BioSpace News Archive

Hummingbird Bioscience and The University of Texas MD Anderson Cancer Center announced the launch of a multi-year strategic research collaboration to investigate and evaluate HMBD-002, Hummingbird’s VISTA antagonist antibody.

Arch Therapeutics, Inc. today announced that Dan Yrigoyen has joined the organization as Vice President of Sales.

Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced new analyses from multiple studies of rezafungin, Cidara’s novel, once-weekly echinocandin, under investigation in Phase 3 development for the treatment of candidemia.

BriaCell Therapeutics Corp. today announced that Dr. William V. Williams, President & CEO of BriaCell, is scheduled to present in virtual conferences.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, announced the appointment of Octávio Costa, MD, as Chief Medical Officer.

CVRx, Inc., a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, announces the addition of Martha Shadan to the company’s Board of Directors.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced three oral presentations demonstrating the potential clinical utility of ibrexafungerp at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Allena Pharmaceuticals, Inc. provided progress updates on its clinical programs: ALLN-346, a first-in-class, oral urate degrading enzyme in development for the treatment of patients with hyperuricemia and gout in the setting of chronic kidney disease and reloxaliase, a first-in-class, oral oxalate degrading enzyme in development for the treatment of patients with enteric hyperoxaluria.

Recce Pharmaceuticals Ltd (ASX:RCE) (FSE:R9Q), the Company developing new classes of synthetic anti-infectives is pleased to announce multiple patients have been dosed with RECCE® 327 (R327) in a topical Phase I/II clinical trial at the Fiona Stanley Hospital Burns Unit in Perth, Western Australia

BioAgilytix welcomes Amanda L. Hays , Ph.D. to its team as Scientific Officer.